Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 20 of 110 Updated Nov 17, 2026

Tesamorelin

TH9507 · Egrifta

FDA-APPROVED · GHRH ANALOG (FDA-APPROVED)

▓ 127 indexed citations across PubMed (84), ClinicalTrials.gov (23), EuropePMC (20).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

127 citations across 9 tiers

Tap any tier to jump to that section of the bibliography.

Background

Tesamorelin is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.

→ Wikipedia

Mechanism of action

Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion

Researched effects

Reduces visceral abdominal fat (HIV lipodystrophy); lowers triglycerides; modest IGF-1 rise

Reported efficacy (trial readout)

  • Visceral Fat Reduction 15.4%

    JCEM (Phase 3, 26wk, n=806)

    High confidencen=806Phase 32010
  • Triglyceride Reduction 12.3%

    JCEM (Phase 3, 26wk, n=806)

    High confidencen=806Phase 32010
  • Trunk Fat Reduction 9.2%

    AIDS (Phase 2, 12wk, n=61)

    High confidencen=61Phase 22005

Trial-efficacy data current as of November 16, 2026.

Live evidence

FDA label safety

Contraindications

4 CONTRAINDICATIONS EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis ( 4 ) Patients with active malignancy ( 4 ) Patients with known hypersensitivity to tesamorelin or excipients in EGRIFTA SV ( 4 ) Pregnancy ( 4 ) EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma. Patients with active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy [see…

Full FDA label (DailyMed) →

Recent literature

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

2 mg SC daily (FDA label)

→ FDA Egrifta (tesamorelin) prescribing information, 2 mg SC daily for HIV-associated lipodystrophy

Known concerns

Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

    Obesity research & clinical practice · 2026 — META-ANALYSES · AUTHORITY 94.5

  2. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

    Journal of the International Association of Providers of AIDS Care · 2026 — META-ANALYSES · AUTHORITY 94.5

  3. Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content.

    2025 — META-ANALYSES · AUTHORITY 94.5

  4. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

    JAMA · 2014 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 91.4

  5. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

    JAMA neurology · 2013 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 83.3

  6. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

    HIV medicine · 2011 — SYSTEMATIC REVIEWS · AUTHORITY 83.1

  7. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

    The Journal of clinical endocrinology and metabolism · 2014 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 77.4

  8. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

    The Journal of clinical endocrinology and metabolism · 2012 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 77.2

  9. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

    The Journal of infectious diseases · 2025 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.5

  10. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

    AIDS (London, England) · 2024 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.4

Full citation library

Year distribution

Meta-Analyses

3
  1. 1.

    Badran AS, Helal A, Shata KS, Ayesh H · Obesity research & clinical practice · 2026 · PMID 41545261

    HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in…

  2. 2.

    Zhu H, Xu L, Lv Y, Yang J, Huang J, Zheng Q, Ji G, Li L. · 2025 · PMID 40026701

    <h4>Background and aims</h4>This study aims to conduct a comprehensive quantitative analysis of various nonalcoholic fatty liver disease (NAFLD) therapeutics, utilizing magnetic resonance (MR)-detected liver fat content (LFC) as the efficacy endpoint, and to identify biomarkers correlated with changes in LFC based on published literature.<h4>Methods</h4>We performed a systematic search of public databases for placebo-controlled randomized trials on NAFLD up to September 29, 2023. A random-effect…

  3. 3.

    Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, et al. · Journal of the International Association of Providers of AIDS Care · 2026 · PMID 42538058

    BackgroundHIV-associated lipodystrophy, a complication of combined antiretroviral therapy (CART), causes significant physical and psychological distress in people living with HIV (PLWH), compromising treatment adherence. Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, has emerged as a therapeutic option.ObjectiveTo systematically evaluate the efficacy and safety of tesamorelin in HIV-infected individuals with lipodystrophy receiving CART, incorporating GRADE assessment.MethodsWe…

Systematic Reviews

1
  1. 4.

    Sivakumar T, Mechanic O, Fehmie DA, Paul B · HIV medicine · 2011 · PMID 21265979

    HIV-associated lipodystrophy is a disorder of fat metabolism that occurs in patients with HIV infection. It can cause metabolic derangements and negative self-perceptions of body image, and result in noncompliance with highly active antiretroviral therapy (HAART). Growth hormone (GH) axis drugs have been evaluated for treatment of this disorder, but no systematic review has been conducted previously. The aim of the review was to compare the effects of GH axis drugs vs. placebo in changing viscer…

Randomised Controlled Trials

22
  1. 5.

    Russo SC, Ockene MW, Arpante AK, Johnson JE, et al. · AIDS (London, England) · 2024 · PMID 38905488

    Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-bas…

  2. 6.

    Ellis RJ, Vaida F, Hu K, Dube M, et al. · The Journal of infectious diseases · 2025 · PMID 39813152

    In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. This 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard o…

  3. 7.

    Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, et al. · JCI insight · 2020 · PMID 32701508

    Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analog tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over 1 year. As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with H…

  4. 8.

    Falutz J, Allas S, Kotler D, Thompson M, et al. · AIDS (London, England) · 2005 · PMID 16052083

    To investigate the effects of TH9507, a novel growth hormone releasing factor, on abdominal fat accumulation, metabolic and safety parameters in HIV-infected patients with central fat accumulation. Randomized, double-blind, placebo-controlled trial enrolling 61 HIV-infected patients with increased waist circumference and waist-to-hip ratio. Participants were randomized to placebo or 1 or 2 mg TH9507 subcutaneously, once daily for 12 weeks. The primary outcome was change in abdominal fat, assesse…

  5. 9.

    González-Sales M, Barrière O, Tremblay PO, Nekka F, et al. · Clinical pharmacokinetics · 2015 · PMID 25358450

    Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about the pharmacokinetics of this compound. Consequently, the aim of this study was to characterize the population pharmacokinetics of tesamorelin in HIV-infected patients and healthy subjects. A total of 38 HIV-infected patients and healthy subjects receivin…

  6. 10.

    Stanley TL, Falutz J, Marsolais C, Morin J, et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012 · PMID 22495074

    Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 months in individuals with human immunodeficiency virus (HIV)-associated abdominal adiposity, but it is unknown whether VAT reduction is directly associated with endocrine and metabolic changes. In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdominal fat accumulation were randomly assigned (ratio, 2:1) to receive tesamorelin or placebo for 2…

  7. 11.

    Falutz J, Allas S, Blot K, Potvin D, et al. · The New England journal of medicine · 2007 · PMID 18057338

    Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with an increased cardiovascular risk. We assessed the use of a growth hormone-releasing factor analogue, tesamorelin, to decrease visceral adiposity. We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamoreli…

  8. 12.

    Braun LR, Feldpausch MN, Czerwonka N, Torriani M, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017 · PMID 29031905

    Fibroblast growth factor 21 (FGF21) ameliorates steatohepatitis but is increased in humans with fatty liver, potentially due to compensatory mechanisms and/or FGF21 resistance. Further, animal models suggest that GH increases serum FGF21. Tesamorelin, a growth hormone releasing hormone agonist, reduces liver fat in HIV-infected individuals. The objectives of this study were to investigate changes in FGF21 during tesamorelin treatment, to elucide the interplay between FGF21, GH augmentation, and…

  9. 13.

    Stanley TL, Fourman LT, Feldpausch MN, Purdy J, et al. · The lancet. HIV · 2019 · PMID 31611038

    Non-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamorelin on liver fat and histology in people with HIV and NAFLD. This randomised, double-blind, multicentre study with identical placebo as a comparator was done in a hospital and a medical research centre in the USA. People with HIV infection and a hepatic fat fraction (HFF) of 5%…

  10. 14.

    Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK · The Journal of clinical endocrinology and metabolism · 2014 · PMID 24178787

    Few studies have assessed the relationship between GH and mitochondrial function. The objective of this study was to determine the effects of improving IGF-I using a GHRH analog, tesamorelin, on mitochondrial function assessed by phosphocreatine (PCr) recovery using (31)P magnetic resonance spectroscopy in obese adults with reduced GH. A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of…

  11. 15.

    Stanley TL, Falutz J, Mamputu JC, Soulban G, et al. · AIDS (London, England) · 2011 · PMID 21516030

    To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic markers and to relate these effects to changes in visceral adipose tissue (VAT). Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks. Circulating plasminogen activator inhibitor-1 (PAI-1) antigen, tissue plasminogen activator (tPA) antigen, C-reactive protein (CRP),…

  12. 16.

    Stanley TL, Feldpausch MN, Oh J, Branch KL, et al. · JAMA · 2014 · PMID 25038357

    Among patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown. To investigate the effect of tesamorelin on visceral and liver fat. Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected men and women with abdomina…

  13. 17.

    Falutz J, Potvin D, Mamputu JC, Assaad H, et al. · Journal of acquired immune deficiency syndromes (1999) · 2010 · PMID 20101189

    HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this population. We investigated the effects of tesamorelin (GHRH(1-44)) in HIV-infected patients with central fat accumulation. A 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy was conducted between January 2007 and October 2008. The study consisted of 2…

  14. 18.

    Adrian S, Scherzinger A, Sanyal A, Lake JE, et al. · The Journal of frailty & aging · 2019 · PMID 31237318

    Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue in people living with HIV, however, the effects on skeletal muscle fat and area are unknown. The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area). Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials. U.S. and Canadian sites. People living with HIV and with abdominal obesity. T…

  15. 19.

    Mangili A, Falutz J, Mamputu JC, Stepanians M, et al. · PloS one · 2015 · PMID 26457580

    Tesamorelin, a synthetic analog of human growth hormone-releasing factor, decreases visceral adipose tissue (VAT) in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. 1) To evaluate the utility of patient characteristics and validated disease-risk scores, namely indicator variables for the metabolic syndrome defined by the International Diabetes Federation (MetS-IDF) or the National Cholesterol Education Program (MetS-NCEP) and the Framingham Risk Score (FRS), as predictor…

  16. 20.

    Falutz J, Allas S, Mamputu JC, Potvin D, et al. · AIDS (London, England) · 2008 · PMID 18690162

    Treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids. The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin. HIV patients with central fat accumulation in the context of antiretroviral therapy were randomized to tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. daily for 26 weeks. At week 26, pati…

  17. 21.

    Clemmons DR, Miller S, Mamputu JC · PloS one · 2017 · PMID 28617838

    Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes. A 12-week randomized, placebo-controlled study of 53 patients with type 2 diabetes. Three treatment groups: placebo, 1 and 2 mg tesamorelin. Fasting glucose, glucose and insulin from oral glucose tolerance test, glycosylated hemoglobin (…

  18. 22.

    Stanley TL, Fourman LT, Wong LP, Sadreyev R, et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 · PMID 33852720

    The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modulates critical metabolic pathways; however, little is known regarding effects of augmenting pulsatile GH secretion on immune function in humans. This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD). 92 b…

  19. 23.

    Makimura H, Feldpausch MN, Rope AM, Hemphill LC, et al. · The Journal of clinical endocrinology and metabolism · 2012 · PMID 23015655

    Obesity is associated with reduced GH secretion and increased cardiovascular disease risk. We performed this study to determine the effects of augmenting endogenous GH secretion on body composition and cardiovascular disease risk indices in obese subjects with reduced GH secretion. A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion. Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for…

  20. 24.

    Fourman LT, Stanley TL, Zheng I, Pan CS, et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 · PMID 32270862

    Nonalcoholic fatty liver disease (NAFLD) affects more than one-third of people living with human immunodeficiency virus (HIV). Nonetheless, its natural history is poorly understood, including which patients are most likely to have a progressive disease course. We leveraged a randomized trial of the growth hormone-releasing hormone analogue tesamorelin to treat NAFLD in HIV. Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsi…

  21. 25.

    Friedman SD, Baker LD, Borson S, Jensen JE, et al. · JAMA neurology · 2013 · PMID 23689947

    Growth hormone-releasing hormone (GHRH) has been previously shown to have cognition-enhancing effects. The role of neurotransmitter changes, measured by proton magnetic resonance spectroscopy, may inform the mechanisms for this response. To examine the neurochemical effects of GHRH in a subset of participants from the parent trial. Randomized, double-blind, placebo-controlled substudy of a larger trial. Clinical research unit at the University of Washington School of Medicine. Thirty adults (17…

  22. 26.

    Baker LD, Barsness SM, Borson S, Merriam GR, et al. · Archives of neurology · 2012 · PMID 22869065

    Growth hormone–releasing hormone(GHRH), growth hormone, and insulin like growth factor 1 have potent effects on brain function, their levels decrease with advancing age, and they likely play a role in the pathogenesis of Alzheimer disease. Previously, we reported favorable cognitive effects of short-term GHRH administration in healthy older adults and provided preliminary evidence to suggest a similar benefit in adults with mild cognitive impairment (MCI). To examine the effects of GHRH on cogni…

Clinical Trials

3
  1. 27.

    González-Sales M, Barrière O, Tremblay PO, Nekka F, et al. · Journal of pharmacokinetics and pharmacodynamics · 2015 · PMID 25895899

    The objective of this analysis was to characterize the time course of selected pharmacodynamic (PD) markers of tesamorelin: growth hormone (GH) and insulin-like growth factor (IGF-1) concentrations in HIV-infected patients and healthy volunteers. A total of 41 subjects in Phase I trials receiving subcutaneous daily doses of 1 or 2 mg of tesamorelin during 14 consecutive days were included in this analysis. A previous pharmacokinetic (PK) model of tesamorelin was used as the input function for th…

  2. 28.

    Makimura H, Stanley TL, Chen CY, Branch KL, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2011 · PMID 21531600

    Obesity is associated with both reduced growth hormone (GH) and adiponectin. However, the relationship between adiponectin and parameters of endogenous GH secretion remains unknown. The aim of this study was to determine the relationship between total and high molecular weight (HMW) adiponectin and parameters of endogenous pulsatile GH secretion and the effects of tesamorelin, a synthetic GH releasing hormone (GHRH(1-44)), on total and HMW adiponectin. A 2-week interventional study with tesamore…

  3. 29.

    Erlandson KM, Gustafson L, Johnson JE, Kulik GL, et al. · BMJ open · 2026 · PMID 42419889

    The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function. TRIUMPH is a two-site, double-blind, randomised trial of 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Enrolled participants will…

Trial Registrations (ClinicalTrials.gov)

23
  1. 30.

    NCT02572323 · Phase 2 · Completed · 2017

    Conditions: Mild Cognitive Impairment

  2. 31.

    NCT03150511 · Phase 2 · Recruiting · 2018

    Conditions: Peripheral Nerve Injuries

  3. 32.

    NCT03226821 · Phase 4 · Terminated · 2018

    Conditions: HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition

  4. 33.

    NCT00608023 · Phase 3 · Completed · 2007

    Conditions: Lipodystrophy, HIV Infections

  5. 34.

    NCT02196831 · NA · Completed · 2015

    Conditions: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)

  6. 35.
  7. 36.

    NCT00795210 · NA · Completed · 2009

    Conditions: HIV Lipodystrophy

  8. 37.

    NCT01263717 · NA · Completed · 2010

    Conditions: HIV, HIV Lipodystrophy

  9. 38.

    NCT07481734 · Phase 2 · Recruiting · 2026

    Conditions: Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis

  10. 39.

    NCT00675506 · Phase 2 · Completed · 2008

    Conditions: Abdominal Obesity, Growth Hormone Deficiency

  11. 40.

    NCT01591902 · Phase 4 · Terminated · 2012

    Conditions: Diabetic Retinopathy, HIV

  12. 41.

    NCT01788462 · Withdrawn · 2012

    Conditions: Lipodystrophy

  13. 42.

    NCT02553603 · Phase 1 · Completed · 2017

    Conditions: Mild Cognitive Impairment

  14. 43.

    NCT01579695 · Terminated · 2013

    Conditions: HIV

  15. 44.

    NCT00123253 · Phase 3 · Completed · 2005

    Conditions: HIV Infections, Lipodystrophy

  16. 45.

    NCT00850564 · NA · Completed · 2009

    Conditions: Healthy Volunteers

  17. 46.

    NCT01388920 · Phase 2 · Terminated · 2011

    Conditions: Chronic Obstructive Pulmonary Disease (COPD)

  18. 47.

    NCT02931474 · Phase 2 · Withdrawn · 2016

    Conditions: Sleep Disorder, Traumatic Brain Injury

  19. 48.

    NCT06554717 · Phase 2 · Recruiting · 2025

    Conditions: HIV-1-infection, Frailty, Impaired Physical Function (+2)

  20. 49.

    NCT01632592 · NA · Withdrawn · 2014

    Conditions: Abdominal Obesity

  21. 50.

    NCT00257712 · Phase 2 · Completed · 2006

    Conditions: Aging, Mild Cognitive Impairment

  22. 51.

    NCT03375788 · Phase 2 · Completed · 2019

    Conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal (+2)

  23. 52.

    NCT01264497 · Phase 2 · Completed · 2002

    Conditions: Type 2 Diabetes

Reviews

18
  1. 53.

    Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

    Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodel…

  2. 54.

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, et al. · The American journal of sports medicine · 2026 · PMID 41476424

    Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides. To evaluate the curre…

  3. 55.

    Dhillon S · Drugs · 2011 · PMID 21668043

    Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat a…

  4. 56.

    Spooner LM, Olin JL · The Annals of pharmacotherapy · 2012 · PMID 22298602

    To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection. Literature was obtained through MEDLINE (1948-November 2011) and International Pharmaceutical Abstracts (1970-October 2011) using the search terms tesamorelin, TH9507, growth hormone releasing factor, and HIV-associated lipodystrophy syndrome. Additional publications were obta…

  5. 57.

    Dhillon S · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2011 · PMID 22050344

    Tesamorelin (Egrifta™) is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat acc…

  6. 58.

    Tomlinson B · Current opinion in investigational drugs (London, England : 2000) · 2006 · PMID 17086939

    Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Pha…

  7. 59.

    Wang Y, Tomlinson B · Expert opinion on investigational drugs · 2009 · PMID 19243281

    The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human growth hormone (rhGH) in therapy for growth hormone (GH)-deficient disorders has led to the development of human growth hormone releasing factor (GFR) analogues, which may be better tolerated. Tesamorelin, a synthetic GFR, has been developed as a potential treatment for a variety of conditions that may be associated with a relative deficiency of GH including HIV-related lipodystroph…

  8. 60.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objecti…

  9. 61.

    Rochira V, Guaraldi G · Best practice & research. Clinical endocrinology & metabolism · 2017 · PMID 28477736

    Treatment with highly active antiretroviral drugs (HAART) is associated with several endocrine and metabolic comorbidities. Pituitary growth hormone (GH) secretion seems to be altered in human immunodeficiency virus (HIV) infection, and about one-third of patients have biochemical GH deficiency (GHD). We undertake a historical review of the functioning of the GH/insulin-like growth factor-1 (IGF-1) axis in patients with acquired immunodeficiency syndrome, and provide an overview of the main chan…

  10. 62.

    Jain S, Desai N, Bhangoo A · Reviews in endocrine & metabolic disorders · 2013 · PMID 23657561

    Aberrations in GHRH-GH -IGF-I axis are common in the complex of HIV, HAART and AIDS. There are 2 distinct mechanisms at play in HIV and AIDS. One is primarly associated with development of lipodystrophy and results in complications such as chronic inflammation, insulin resistance, lipid and metabolic abnormalities. HIV lipodystrophy is found especially in those on highly active anti-retroviral therapy (HAART). The various processes involved in lipodystrophy result in the suppression of pituitary…

  11. 63.

    Leung VL, Glesby MJ · Current opinion in infectious diseases · 2011 · PMID 21124215

    This review addresses our current understanding of the pathogenesis of HIV-associated lipohypertrophy and describes an evidence-based approach to treatment. Although the pathogenesis of HIV-associated lipohypertrophy remains elusive, recent clinical and laboratory investigations in fatty acid metabolism and growth hormone dynamics have furthered our understanding of the condition. These findings have also paved the way for new therapeutic interventions, of which tesamorelin, an analog of growth…

  12. 64.

    Arora G, Conde KR, Desouza CV · Journal of clinical medicine · 2026 · PMID 41598480

  13. 65.

    Tuffaha SH, Singh P, Budihardjo JD, Means KR, et al. · Expert opinion on therapeutic targets · 2016 · PMID 27192539

    Peripheral nerve injuries often result in debilitating motor and sensory deficits. There are currently no therapeutic agents that are clinically available to enhance the regenerative process. Following surgical repair, axons often must regenerate long distances to reach and reinnervate distal targets. Progressive atrophy of denervated muscle and Schwann cells (SCs) prior to reinnervation contributes to poor outcomes. Growth hormone (GH)-based therapies have the potential to accelerate axonal reg…

  14. 66.

    Hu M, Tomlinson B · Current opinion in investigational drugs (London, England : 2000) · 2010 · PMID 20872317

    HIV-associated lipodystrophy characterized by body composition changes and associated metabolic abnormalities, including dyslipidemia and insulin resistance, is a major challenge in the treatment of HIV infection. Growth hormone-releasing factor (GRF) analogs with greater stability than the natural hormone can induce growth hormone secretion in a physiological manner, and appear to be promising candidate therapies for these conditions. The most promising GRF agonist in development is tesamorelin…

  15. 67.

    Moyle G, Moutschen M, Martínez E, Domingo P, et al. · AIDS reviews · 2010 · PMID 20216906

    Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased abdominal circumference and visceral adiposity were first recognized in the late 1990s, soon after the advent of effective combination antiretroviral therapy. Visceral adiposity is commonly associated with metabolic abnormalities including low HDL-cholesterol, raised triglycerides, insulin resistance, and hypertension, a constellation of risk factors for cardiovascular diseas…

  16. 68.

    Renke G, Chinellato L · International journal of molecular sciences · 2026 · PMID 42123471

    Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes. While several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement. Our objective is to present the effects, clinical applications, safety profiles, and regulatory status of prominent peptides used…

  17. 69.

    Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, et al. · JBJS reviews · 2026 · PMID 42160466

    Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus. To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outcomes. Structured narrative review.…

  18. 70.

    Vasylieva V, West A, Karpman E · Sexual medicine reviews · 2026 · PMID 42862021

    Peptide-based therapies are increasingly used in urology and sexual medicine, although adoption is often influenced by off-label prescribing, direct-to-consumer promotion, and limited long-term safety data. We review mechanisms, clinical evidence, dosing, safety, and regulatory status of these agents. A structured search of PubMed, Scopus, and Google Scholar identified studies of peptide-based therapies in sexual medicine. Search terms included Bremelanotide, Melanotan II, Kisspeptin, Oxytocin,…

Research Articles

52
  1. 71.

    Grunfeld C, Dritselis A, Kirkpatrick P · Nature reviews. Drug discovery · 2011 · PMID 21283099

    In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

  2. 72.

    O'Neal R · BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · 2010 · PMID 21591600

  3. 73.

    Memdouh S, Gavrilović I, Ng K, Cowan D, et al. · Drug testing and analysis · 2021 · PMID 34665524

    The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Although there is evidence of their use, based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories. This might be due to their small concentration in urine and limited knowledge about their metabolism, especially for unapproved synthetic analogs. This study investigates the in vitro m…

  4. 74.

    Falutz J, Mamputu JC, Potvin D, Moyle G, et al. · The Journal of clinical endocrinology and metabolism · 2010 · PMID 20554713

    HIV patients treated with antiretroviral therapy (ART) often develop increased visceral adipose tissue (VAT). Our objective was to perform a pooled analysis of two phase-3 studies of tesamorelin in ART-treated HIV patients with excess abdominal fat. Two multicenter, international studies were conducted; a 26-wk randomized, placebo-controlled primary intervention phase was followed by a 26-wk safety extension. A total of 806 ART-treated HIV patients with excess abdominal fat were randomized in a…

  5. 75.

    Lake JE, La K, Erlandson KM, Adrian S, et al. · AIDS (London, England) · 2021 · PMID 33756511

    Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density = smaller, higher quality adipocytes). We assessed the effects of tesamorelin, a growth hormone-releasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV (PWH), on fat density. Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were in…

  6. 76.

    Fourman LT, Stanley TL, Billingsley JM, Sui SJH, et al. · Scientific reports · 2021 · PMID 34006921

    NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division. Nonetheless, effects of tesamorelin on individual plasma proteins pertaining to these pathways are not known. Leveraging our prior randomized-controlled trial a…

  7. 77.

    Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, et al. · AIDS (London, England) · 2017 · PMID 28832410

    Tesamorelin reduces visceral adipose tissue (VAT) in HIV. We investigated whether reductions in VAT with tesamorelin are associated with changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). We utilized data from two multicenter Phase III trials of tesamorelin among 806 HIV-infected patients with abdominal obesity. These studies showed that the majority of patients treated with tesamorelin are 'responders', defined a priori by the Food and Drug Administration as achievi…

  8. 78.

    Ferdinandi ES, Brazeau P, High K, Procter B, et al. · Basic & clinical pharmacology & toxicology · 2007 · PMID 17214611

    TH9507, an analogue of human growth hormone-releasing factor (hGRF1-44NH2) minimally modified by addition of a trans-3-hexenoyl moiety to Tyr1 of the amino acid sequence, was found to be resistant to dipeptidyl aminopeptidase-IV deactivation. Compared to natural hGRF1-44NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma and prolonged the in vivo plasma elimination kinetics of immunoreactive TH9507. Plasma growth hormone and insulin-like growth facto…

  9. 79.

    Jansen M, Darby I, Abribat T, Dubreuil P, et al. · International journal of pharmaceutics · 2004 · PMID 15113616

    A modified growth hormone releasing factor (GRF; TH9507), a 44 amino acid peptide analogue of natural human growth hormone releasing factor, is being developed for the treatment of age-associated conditions resulting from diminished growth hormone (GH) secretion. The inhalation route of administration is being considered as an alternative to subcutaneous injection. A study was undertaken in dogs to investigate the absorption of TH9507 following pulmonary delivery. Male beagle dogs were administe…

  10. 80.

    Rahman F, McLaughlin T, Mesquita P, Morin J, et al. · Journal of clinical and translational science · 2023 · PMID 36845310

    Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did no…

  11. 81.

    Stanley TL, Chen CY, Branch KL, Makimura H, et al. · The Journal of clinical endocrinology and metabolism · 2011 · PMID 20943777

    Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH(1-44)) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men. Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after…

  12. 82.

    Teng S, Potvin D, Mamputu JC, Vincent G, et al. · Clinical pharmacology in drug development · 2013 · PMID 27121785

    The potential impact of tesamorelin on CYP3A activity was investigated by examining its effect on the pharmacokinetics of simvastatin and ritonavir. In two randomized, two-way crossover studies, subjects were administered 2 mg tesamorelin on Days 1-7 with 80 mg simvastatin or 100 mg ritonavir co-administered on Day 6 (Treatment A), and a single dose of simvastatin or ritonavir alone on Day 6 (Treatment B). Pharmacokinetic samples were collected on Day 6 to measure simvastatin, ritonavir and tesa…

  13. 83.

    Monroe A · BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · 2007 · PMID 18069152

    As the use of highly active antiretroviral therapy (HAART) became widespread, HIV positive individuals and their physicians began to notice changes in body fat distribution, with excess fat or fat loss noted in different areas. These body shape changes are sometimes accompanied by metabolic abnormalities, such as insulin resistance and elevated blood fats. Collectively, these changes are known as lipodystrophy syndrome. Treatment options for lipodystrophy are somewhat limited. Growth hormone has…

  14. 84.

    Knoop A, Thomas A, Fichant E, Delahaut P, et al. · Analytical and bioanalytical chemistry · 2016 · PMID 26879649

    The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). The aim of the present study was to develop a method for the simultaneous detection of four different GHRHs and respective metabolites from human plasma by means of immunoaffinity purification and subsequent nano-ultrahigh performance liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry. The target analytes included Geref (Ser…

  15. 85.

    Bedimo R · HIV/AIDS (Auckland, N.Z.) · 2011 · PMID 22096409

    HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause significant patient distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment options - including antiretroviral switch, insulin sensitizers, and surgical approaches - have been associated with limited success and potential com…

  16. 86.

    McLarnon A · Nature reviews. Endocrinology · 2012 · PMID 22926095

  17. 87.

    Chege BM, Mwangi PW, Githinji CG, Bukachi F · PloS one · 2024 · PMID 38416754

    This study investigated the interactions between a low protein high calorie (LPHC) diet and an integrase inhibitor-containing antiretroviral drug regimen (INI-CR)in light of evidence suggesting that the initiation of cART in patients with poor nutritional status is a predictor of mortality independent of immune status. Freshly weaned Sprague Dawley rats (120) were randomized into the standard, LPHC and normal protein high calorie (NPHC) diet groups (n = 40/group) initially for 15 weeks. Thereaft…

  18. 88.

    Cristea CD, Radu M, Toboc A, Stan C, et al. · Analytical biochemistry · 2023 · PMID 37806509

    The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)…

  19. 89.

    Berger D · Positively aware : the monthly journal of the Test Positive Aware Network · 2008 · PMID 18724445

  20. 90.

    Audsley J, Sasadeusz J, Lewin SR · The lancet. HIV · 2019 · PMID 31611037

  21. 91.

    Grodeck B · Positively aware : the monthly journal of the Test Positive Aware Network · 2008 · PMID 18828236

  22. 92.

    TreatmentUpdate · 2007 · PMID 17575575

  23. 93.

    Patel A, Gandhi H, Upaganlawar A · Journal of pharmacy & bioallied sciences · 2011 · PMID 21687371

  24. 94.

    Traynor K · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2010 · PMID 21115997

  25. 95.

    Thomas A, Walpurgis K, Thevis M · Journal of mass spectrometry : JMS · 2024 · PMID 38197510

    Peptides with a molecular mass between 2 and 10 kDa that are prohibited in elite sports usually require dedicated sample preparation and mass spectrometric detection that commonly cannot be combined with other (lower molecular mass) substances. In most instances, the physicochemical differences are too significant to allow for a generic analytical procedure. A simplification of established and comparably complex analytical approaches is therefore desirable and has been accomplished in the contex…

  26. 96.

    Thomas A, Thilmany S, Hofmann A, Thevis M · Analytical science advances · 2022 · PMID 38716080

    Bioactive peptides with a molecular mass between 2 and 10 kDa represent an important class of substances banned in elite sports, which has been recognized with an increasing number and variety of substances by anti-doping organizations. Also, the annually renewed list of prohibited substances of the World Anti-Doping Agency (WADA) explicitly mentions more and more of these peptides, and efficient testing procedures are required. Even under simplified sample preparation conditions, liquid chromat…

  27. 97.

    Falutz J · Drugs of today (Barcelona, Spain : 1998) · 2011 · PMID 21695284

    Metabolic complications are common in treated HIV patients. Their etiology is multifactorial and the development of increased abdominal fat contributes to cardiovascular risk and impaired quality of life. Treated patients with fat mass distribution changes have relative growth hormone deficiency. Both pharmacologic and physiologic doses of growth hormone reduce the increased visceral adipose tissue and improve the associated abnormal lipid profiles in short-term studies. However, impaired glucos…

  28. 98.

    Mateo MG, Gutiérrez MDM, Domingo P · Expert review of endocrinology & metabolism · 2011 · PMID 30764032

    Morphologic and metabolic abnormalities remain a common problem in patients with HIV-1 infection, which contributes to poor self image and may negatively impact on patient's adherence to medication and success of therapy. In addition, these physiological and metabolic changes can lead to increased cardiovascular risk. In such patients, excess central fat could be associated with loss of subcutaneous fat. Several strategies to decrease the excess of visceral fat have been assessed. Tesamorelin, a…

  29. 99.

    TreatmentUpdate · 2007 · PMID 17571443

  30. 100.

    Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, et al. · Drug testing and analysis · 2015 · PMID 26382721

    Bioactive peptides with an approximate molecular mass of 2-12 kDa are of considerable relevance in sports drug testing. Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glulisine, glargine, detemir, degludec, bovine and porcine insulin), synthetic ACTH (synacthen), synthetic IGF-I (lon…

  31. 101.

    Jain SS, Ramteke KB, Raparti GT, Kalra S · Indian journal of endocrinology and metabolism · 2012 · PMID 22701839

    Enhanced understanding about the way human immunodeficiency virus (HIV) infects and causes infection in humans has led to invention and use of newer more effective antiretroviral drugs. As treatment for HIV is long term, side effects of the antiretrovirals become an important area of research focus. Antiretrovirals can cause severe metabolic abnormalities, collectively known as HIV lipodystrophy syndrome. If untreated, these metabolic abnormalities have the potential to increase stroke and cardi…

  32. 102.

    Coppieters G, Deventer K, Polet M, Van Eenoo P, et al. · Journal of pharmaceutical and biomedical analysis · 2022 · PMID 35298973

    This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS. Sample preparation avoids the use of laborious antibody-based extraction approaches and consists solely of preconcentration by ultrafiltration. Even in the absence of immuno-affinity purification steps, high sensitivity was still ensured as…

  33. 103.

    Chege BM, Mwangi PW, Githinji CG, Bukachi F · Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026 · PMID 42018810

    The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV. This study investigated the interaction between cART regimens and dietary composition on electrocardiographic (ECG) parameters and myocardial histopathology. A total of 120 weanling Sprague Daw…

  34. 104.

    Pont L, Alechaga É, Terrero A, Monfort N, et al. · Journal of chromatography. A · 2020 · PMID 32971474

    Growth hormone-releasing hormone and its analogues sermorelin, tesamorelin and CJC-1295 are included in the prohibited list of the World Antidoping Agency. These target peptides are found at very low concentrations in urine (at the pg/mL level). For this reason, hyphenated enrichment and purification steps prior to mass spectrometric detection are required. Among different strategies, immunopurification based on magnetic beads is an excellent alternative, as it offers improved selectivity when t…

  35. 105.

    Uçaktürk E, Nemutlu E · Journal of pharmaceutical and biomedical analysis · 2026 · PMID 41138283

    Growth hormone-releasing hormone (GHRH) and its synthetic analogs are considered performance-enhancing substances and are therefore prohibited by the World Anti-Doping Agency (WADA). The analysis of GHRH and its analogs in urine presents significant analytical challenges due to their inherent in vivo instability, rapid renal clearance, and low urinary concentrations. The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both…

  36. 106.
  37. 107.

    Pryke L, Koethe JR, Bailin S. · 2026 · PMID 41733834

    <h4>Purpose of review</h4>People living with HIV (PLWH) on contemporary antiretroviral therapy experience high rates of overweight/obesity, which predisposes to cardiometabolic disease and multiple other conditions with negative health consequences in this aging population. We aim to summarize the epidemiology and pathophysiology of obesity in PLWH and review recent advances in the therapeutic management of obesity.<h4>Recent findings</h4>The prevalence of overweight/obesity in PLWH mirrors long…

  38. 108.
  39. 109.

    Al Musaimi O. · 2024 · PMID 38540684

    Peptides continue to gain significance in the pharmaceutical arena. Since the unveiling of insulin in 1921, the Food and Drug Administration (FDA) has authorised around 100 peptides for various applications. Peptides, although initially derived from endogenous sources, have evolved beyond their natural origins, exhibiting favourable therapeutic effectiveness. Medicinal chemistry has played a pivotal role in synthesising valuable natural peptide analogues, providing synthetic alternatives with th…

  40. 110.

    Myšková A, Sýkora D, Kuneš J, Maletínská L. · 2023 · PMID 38010881

    Peptides, as potential therapeutics continue to gain importance in the search for active substances for the treatment of numerous human diseases, some of which are, to this day, incurable. As potential therapeutic drugs, peptides have many favorable chemical and pharmacological properties, starting with their great diversity, through their high affinity for binding to all sort of natural receptors, and ending with the various pathways of their breakdown, which produces nothing but amino acids th…

  41. 111.
  42. 112.

    Steenblock C, Bornstein SR. · 2025 · PMID 39560873

    Despite over a century of insulin therapy and recent advances in glucose monitoring, diabetes and its complications remain a significant burden. Current medications are not durable, with symptoms often returning after treatment ends, and responses vary between patients. Additionally, the effectiveness of many medications diminishes over time, highlighting the need for alternative approaches. Maintaining β-cell mass and promoting β-cell regeneration offer more curable treatments, while cell repla…

  43. 113.

    2016 · PMID 30896905

    Tesamorelin (Egrifta) is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference ≥ 95 cm for males and ≥ 94 cm for females, and confirmed by a VAT level > 130 cm2 by computed tomography (CT) scan, in treatment-experienced adult HIV-infected patients with lipodystrophy. The dosage is 2 mg (two 1 mg vials) injected subcutaneously once a day. Treatment with tesamorelin should be limited to patients who failed to reduce excess VAT using diet and exerci…

  44. 114.

    2016 · PMID 30920787

    Human immunodeficiency virus (HIV)–associated lipodystrophy is a medical condition characterized by body composition changes, including lipohypertrophy. Patients with lipohypertrophy typically have excess visceral adipose tissue (VAT) in the abdomen, but may also accumulate fat in other areas of the body. The underlying mechanisms of lipohypertrophy are poorly understood, thus complicating efforts to determine its etiology. Researchers hypothesize its pathogenesis to be related to the virus itse…

  45. 115.
  46. 116.

    Lindner S, Keim S, Haddadzadegan S, Fernandez Romero O, Zöller K, Stern G, Cesi I, Kafedjiiski K, Bernkop-Schnürch A. · 2026 · PMID 41097846

    Macromolecular drugs, including peptides, proteins, oligonucleotides, and polysaccharides, have shown remarkable therapeutic potential due to their high specificity, potency, and low toxicity profiles. However, their clinical translation, particularly for oral administration, remains limited by poor bioavailability arising from poor membrane permeability and enzymatic instability. Enhancing the lipophilicity of these molecules is a critical strategy to overcome these challenges, improving their…

  47. 117.

    Stanley T, Fourman L, Wong L, Sadreyev R, Billingsley J, Feldpausch M, Boutin A, Lee H, Corey K, Torriani M, Kleiner D, Chung R, Hadigan C, Grinspoon S. · 2021

    Abstract Introduction: The GH/IGF-1 axis affects multiple metabolic pathways, and animal models demonstrate that it also modulates immune function. Little is known, however, regarding effects of augmenting GH secretion on immune function in humans. This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and immune-related gene pathways in the liver in people with HIV (PWH) and NAFLD. We hypo…

  48. 118.

    Lamesa TA. · 2024 · PMID 38584795

    Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles publ…

  49. 119.

    Rahman F, de Chantal M, Mesquita P, Aberg J. · 2020

    Abstract <h4>Background</h4> Lipohypertrophy is defined as excess fat deposition in abdominal defined as visceral adipose tissue (VAT) as well as in the dorsocervical region, breasts, trunk, and along with possible fat deposition in liver, muscle, myocardium and epicardium. Multiple factors have been described as contributing to lipohypertrophy in people living with HIV (PLWH), including patient characteristics, antiretroviral therapy (ART) and also impaired growth hormone (GH) secretion. Tesamo…

  50. 120.

    Pedrolli F, Morello G, Gesmundo I, Banfi D, Ferro A, Wangpaichitr M, Sha W, Tamagno E, Schally AV, Guglielmotto M, Granata R. · 2026 · PMID 41946684

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation, and synaptic loss. Existing therapies provide only modest symptomatic relief and fail to slow disease progression. Beyond its role in promoting pituitary growth hormone (GH) secretion, growth hormone-releasing hormone (GHRH) has shown neuroprotective effects in experimental ischemic stroke and spinal muscular atrophy. Here, we explored th…

  51. 121.

    Stanley TL, Fourman LT, Zheng I, McClure CM, Feldpausch MN, Torriani M, Corey KE, Chung RT, Lee H, Kleiner DE, Hadigan CM, Grinspoon SK. · 2021 · PMID 33125080

    <h4>Context</h4>Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD).<h4>Objective</h4>To assess relationships between hepatic expression of IGF1 and IGF-binding proteins (IGFBPs) and measures of glycemia and liver disease in adults with NAFLD. Secondarily to assess effects of GH-releasing hormone (GHRH) on circulating IGFBPs.<h4>Design</h4>Analysis of data from…

  52. 122.

    Colpaert T, Miller G, Goodrum J, Nair V, et al. · Drug testing and analysis · 2026 · PMID 43013893

    Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue used for reducing excess abdominal fat in HIV-infected patients suffering from lipodystrophy. Together with other GHRH analogues, it is classified as a doping agent and is prohibited at all times according to the World Anti-Doping Agency (WADA). To investigate whether current testing methodologies are adequate for detecting tesamorelin abuse, an administration study was performed involving six healthy volunteers and 10 consecutive…

Preprints (not yet peer-reviewed)

3
  1. 123.

    Mendias CL, Awan TM. · 2026

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  2. 124.

    Mendias CL, Awan TM. · 2025

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  3. 125.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

Case Reports

2
  1. 126.

    Fourman LT, Grinspoon SK · The Journal of clinical endocrinology and metabolism · 2022 · PMID 35137140

    Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, suggesting considerable…

  2. 127.

    Beach R, Tims-Cook Z, McGary CS, Thote T · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 42139091

    Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI). This pattern of fat accumulation is associated with metabolic dysfunction, cardiovascular risk, and reduced quality of life. Since EVAF can present without generalized obesity, weight-based assessments may fail to identify it; moreover, addressing EVAF warrants distinct approaches based on a patient's…

Curated sources on file

13
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.

Continue reading